Table 2.

Treatment follow-up in children with refAML after CR1 according to the consolidation with alloHSCT

	AlloHSCT after CR1 (n = 4)	No alloHSCT after CR1 (n = 1)
Death/TRM
Relapse	n = 1, 26 months*	n = 1, 0.3 months*
Survival in CR1	n = 3, 33.2 months** (range 14.9–34.2)

^*Time from CR1 in months

^**Median time from CR1